We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.
- Authors
Yuichiro Yasuda; Yoshihiro Hattori; Rie Tohnai; Shoichi Ito; Yoshitaka Kawa; Yuko Kono; Yoshiko Urata; Munenobu Nogami; Daisuke Takenaka; Shunichi Negoro; Miyako Satouchi
- Abstract
Background: The optimal chemotherapy regimen for non-small cell lung cancer patients with interstitial lung disease is unclear. We therefore investigated the safety and efficacy of carboplatin plus nab-paclitaxel as a first-line regimen for non-small cell lung cancer in patients with interstitial lung disease. Methods: We retrospectively reviewed advanced non-small cell lung cancer patients with interstitial lung disease who received carboplatin plus nab-paclitaxel as a first-line chemotherapy regimen at Hyogo Cancer Center between February 2013 and August 2016. interstitial lung disease was diagnosed according to the findings of pretreatment chest high-resolution computed tomography. Results: Twelve patients were included (male, n = 11; female, n = 1). The overall response rate was 67% and the disease control rate was 100%. The median progression free survival was 5.1 months (95% CI: 2.9-8.3 months) and the median overall survival was 14.9 months (95% CI: 4.8-not reached). A chemotherapy-related acute exacerbation of interstitial lung disease was observed in one patient; the extent of this event was Grade 2. There were no treatment-related deaths. Conclusions: Carboplatin plus nab-paclitaxel, as a first-line chemotherapy regimen for nonsmall cell lung cancer, showed favorable efficacy and safety in patients with preexisting interstitial lung disease.
- Publication
Japanese Journal of Clinical Oncology, 2018, Vol 48, Issue 1, p89
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyx142